Proteins present on the surface of malaria parasites that participate in the process of invasion and adhesion to host cells are considered attractive vaccine targets. Aided by the availability of the partially completed genome sequence of the simian malaria parasite Plasmodium knowlesi, we have identified a 786-bp DNA sequence that encodes a 262-amino-acid-long protein, containing an altered version of the thrombospondin type I repeat domain (SPATR). Thrombospondin type 1 repeat domains participate in biologically diverse functions, such as cell attachment, mobility, proliferation, and extracellular protease activities. The SPATR from P. knowlesi (PkSPATR) shares 61% and 58% sequence identity with its Plasmodium falciparum and Plasmodium yoelii orthologs, respectively. By immunofluorescence analysis, we determined that PkSPATR is a multistage antigen that is expressed on the surface of P. knowlesi sporozoite and erythrocytic stage parasites. Recombinant PkSPATR produced in Escherichia coli binds to a human hepatoma cell line, HepG2, suggesting that PkSPATR is a parasite ligand that could be involved in sporozoite invasion of liver cells. Furthermore, recombinant PkSPATR reacted with pooled sera from P. knowlesi-infected rhesus monkeys, indicating that native PkSPATR is immunogenic during infection. Further efficacy evaluation studies in the P. knowlesi-rhesus monkey sporozoite challenge model will help to decide whether the SPATR molecule should be developed as a vaccine against human malarias.An effective vaccine that reduces malaria-related mortality and morbidity would indeed alleviate the suffering of millions of people around the world (17). The onset and progression of malaria infection require a complex sequence of recognition, adhesion, and invasion events between the parasite and host cells. To accomplish this, the parasite expresses a multitude of proteins on its surface that serve as ligands that interact with the receptors present on the host cells. For example, circumsporozoite protein and thrombospondin-related anonymous protein (two sporozoite-stage proteins) participate in the binding of malaria sporozoites to liver cells (6, 30). In the erythrocytic-stage cycle, erythrocyte-binding antigen 175 is recognized as a merozoite ligand that binds to glycophorin A on erythrocytes to initiate the process of merozoite invasion (33). Likewise, the products of the var genes expressed on the surface of infected erythrocytes facilitate the adherence of mature forms of parasites to deep venules of endothelial cells and thus shield them from clearance by the host immune system.The standard steps in preclinical vaccine development prior to phase I clinical trials in humans are antigen identification, its biochemical/biological characterization, and efficacy evaluation in animal models. For malaria, animal studies are generally performed using pertinent orthologs of Plasmodium falciparum (the most lethal form of human malaria) in the mouse (Plasmodium yoelii/Plasmodium berghei) and monkey (Plasmodium knowlesi) mo...